New Delhi: Biotech firm Biocon on Tuesday said it has … the terms of the agreement, Biocon will be responsible for supplying … in complex peptide development," Biocon CEO and MD Siddharth Mittal … are excited to partner with Biocon for Semaglutide and take …

… terms of this agreement, Biocon will be responsible for … Executive Officer and Managing Director, Biocon Ltd., said, "This … : Equity Bulls Keywords Biocon INE376G01013 Biotechnology Outlicensing AjantaPharma Semaglutide Type2Diabetes GlycemicControl

… Adalimumab, under which Biocon Biologics only had commercialization … inflammatory diseases globally." Biocon Biologics initially acquired the … : Equity Bulls Keywords Biocon INE376G01013 Biotechnology BioconBiologics GlobalRights Hulio Biosimilar …

Biocon Ltd has received an … Administration (US FDA), for our Biocon Generics Inc facility, located in … of October, 2025. Shares of Biocon Limited was last trading in … 00. Source : Equity Bulls Keywords Biocon INE376G01013 Biotechnology USFDA EIR VAIStatus

… In subsequent years, Biocon Biologics has continued this … consecutive year that Biocon and Biocon Biologics have appeared … consecutive year that Biocon and Biocon Biologics have appeared … : Equity Bulls Keywords Biocon INE376G01013 Biotechnology BioconBiologics

… Executive Officer and Managing Director, Biocon Limited, said, "The launch … across regions." Shares of Biocon Limited was last trading in … .00. Source : Equity Bulls Keywords Biocon INE376G01013 Biotechnology GLP1 Peptide Liraglutide Netherlands

… global healthcare and biotechnology. Kiran Mazumdar-Shaw, Chairperson, Biocon Group said, “I … engineering research with India’s biotech and innovation ecosystem, strengthening both … Mazumdar-Shaw is a pioneering biotech entrepreneur, a healthcare visionary, …

… treat multiple ophthalmology conditions. Biocon Biologics, Regeneron and Bayer … CEO & Managing Director, Biocon Biologics, said, "This … : Equity Bulls Keywords Biocon INE376G01013 Biotechnology Settlement License Agreement Biosimilar Aflibercept …

… tide of biotech therapeutics, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Group an … special address at the ETPharma Biotech Leadership Symposium Shaw said, “Future … computational, and every breakthrough in biotech will be driven disciplines including …

… therapeutics. Unlike the traditional trajectory, biotech represents a much higher degree … Shaw, Executive Chairperson – Biocon Limited and Biocon Biologics Limited, will address … Anuj Goel, Chief Development Officer, Biocon Biologics; and Jason Chen, Asia …